Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research
Background Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on‐line hemodiafiltration (OL‐HDF) and HD with medium cut‐off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL‐HDF with FxCordiax HDF 800™, with HD with...
Gespeichert in:
| Veröffentlicht in: | Artificial organs 2023-03, Vol.47 (3), p.589-594 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 594 |
|---|---|
| container_issue | 3 |
| container_start_page | 589 |
| container_title | Artificial organs |
| container_volume | 47 |
| creator | Martínez‐Miguel, Patricia Gimena Muñoz, Rocío Barrionuevo González, Marta López‐Ongil, Susana Moro, María Ángeles Lizasoain, Ignacio Rodríguez‐Puyol, Diego García Segura, Juan Manuel |
| description | Background
Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on‐line hemodiafiltration (OL‐HDF) and HD with medium cut‐off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL‐HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer.
Methods
Fourteen patients following treatment with OL‐HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1‐week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified.
Results
Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL‐ HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL‐HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p |
| doi_str_mv | 10.1111/aor.14466 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2739739575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2739739575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-3a5046a510fda7b5c29d3716679acc1963792c5a670094f2da40a1917971573</originalsourceid><addsrcrecordid>eNp1kc9uVCEUh4mxsWN14QsYEje6uC1c_g3uJhOtTZo0URfubs4At6XhwgiXNuPKR3Dv2_kkpU51YSIhkMDHl3P4IfSCkmPaxgmkfEw5l_IRWlDRi44KzR-jBaGSdELyL4foaSnXhBDFiXyCDpnkPdFsuUA_12naQvYlRZxG3OPJWV8nbOqcxhFbD2H3zeWCb9pSC07x1_cfwUeHr9yU2vXow5xh9u19dpeQrY-X2LptvT-8cRg2Pvh5hyFaDGFTJx9xSKW8xauIazQpzjmF4Cw2TesNhOYpDrK5eoYORgjFPX_Yj9Cn9-8-rz905xenZ-vVeWeYYLJjIAiXICgZLaiNML22TFEplQZjqJZM6d4IkIoQzcfeAidANVVaUaHYEXq9t25z-lpdmYfJF-NCgOhSLUOvmG5TKNHQV_-g16nm2Gpr1FJIKZZMN-rNnjK59ZndOGyznyDvBkqG-7yGltfwO6_Gvnww1k37-b_kn4AacLIHbn1wu_-bhtXFx73yDoCRojA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785665839</pqid></control><display><type>article</type><title>Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Martínez‐Miguel, Patricia ; Gimena Muñoz, Rocío ; Barrionuevo González, Marta ; López‐Ongil, Susana ; Moro, María Ángeles ; Lizasoain, Ignacio ; Rodríguez‐Puyol, Diego ; García Segura, Juan Manuel</creator><creatorcontrib>Martínez‐Miguel, Patricia ; Gimena Muñoz, Rocío ; Barrionuevo González, Marta ; López‐Ongil, Susana ; Moro, María Ángeles ; Lizasoain, Ignacio ; Rodríguez‐Puyol, Diego ; García Segura, Juan Manuel</creatorcontrib><description>Background
Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on‐line hemodiafiltration (OL‐HDF) and HD with medium cut‐off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL‐HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer.
Methods
Fourteen patients following treatment with OL‐HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1‐week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified.
Results
Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL‐ HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL‐HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p < 0.001, respectively). Metabolomic studies suggested, by semi‐quantitative analysis, a greater depurative capacity of OL‐HDF, followed by Elisio 21HX™, and then Theranova 500®.
Conclusions
In this study, HD with Theranova 500® has proven to be very similar in efficacy to OL‐HDF, although with a significantly higher albumin loss. HD with Elisio 21HX™ resulted in lower removal of molecules around 20 000 compared to OL‐HDF, with no significant difference compared to Theranova 500®, and with less albumin loss than Theranova 500®.
The aim of this study was to compare the efficacy and safety of on‐line hemodiafiltration (OL‐HDF), with hemodialysis with 2 medium cutoff dialyzers (Theranova 500® and Elisio 21HX™).
Theranova 500® hemodialysis was very similar in efficacy to OL‐HDF, although with significantly higher albumin loss.
Elisio 21HX™ hemodialysis resulted in a lower removal of molecules with molecular weight around 20 000 compared to OL‐HDF, with no significant differences compared to Theranova 500®, and a lower albumin loss than Theranova 500® and OL‐HDF.</description><identifier>ISSN: 0160-564X</identifier><identifier>EISSN: 1525-1594</identifier><identifier>DOI: 10.1111/aor.14466</identifier><identifier>PMID: 36420938</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Albumin ; albumine ; Albumins ; Albumins - analysis ; Dialyzers ; Effectiveness ; expanded hemodialysis ; Hemodiafiltration - methods ; Hemodialysis ; Humans ; medium cut‐off dialyser ; Metabolomics ; Molecular weight ; NMR ; Nuclear magnetic resonance ; Nuclear safety ; on‐line hemodiafiltration ; Prolactin ; Prospective Studies ; Renal Dialysis - methods ; uremic toxins</subject><ispartof>Artificial organs, 2023-03, Vol.47 (3), p.589-594</ispartof><rights>2022 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.</rights><rights>Copyright © 2023 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-3a5046a510fda7b5c29d3716679acc1963792c5a670094f2da40a1917971573</citedby><cites>FETCH-LOGICAL-c3536-3a5046a510fda7b5c29d3716679acc1963792c5a670094f2da40a1917971573</cites><orcidid>0000-0002-4544-7581</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faor.14466$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faor.14466$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36420938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martínez‐Miguel, Patricia</creatorcontrib><creatorcontrib>Gimena Muñoz, Rocío</creatorcontrib><creatorcontrib>Barrionuevo González, Marta</creatorcontrib><creatorcontrib>López‐Ongil, Susana</creatorcontrib><creatorcontrib>Moro, María Ángeles</creatorcontrib><creatorcontrib>Lizasoain, Ignacio</creatorcontrib><creatorcontrib>Rodríguez‐Puyol, Diego</creatorcontrib><creatorcontrib>García Segura, Juan Manuel</creatorcontrib><title>Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research</title><title>Artificial organs</title><addtitle>Artif Organs</addtitle><description>Background
Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on‐line hemodiafiltration (OL‐HDF) and HD with medium cut‐off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL‐HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer.
Methods
Fourteen patients following treatment with OL‐HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1‐week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified.
Results
Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL‐ HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL‐HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p < 0.001, respectively). Metabolomic studies suggested, by semi‐quantitative analysis, a greater depurative capacity of OL‐HDF, followed by Elisio 21HX™, and then Theranova 500®.
Conclusions
In this study, HD with Theranova 500® has proven to be very similar in efficacy to OL‐HDF, although with a significantly higher albumin loss. HD with Elisio 21HX™ resulted in lower removal of molecules around 20 000 compared to OL‐HDF, with no significant difference compared to Theranova 500®, and with less albumin loss than Theranova 500®.
The aim of this study was to compare the efficacy and safety of on‐line hemodiafiltration (OL‐HDF), with hemodialysis with 2 medium cutoff dialyzers (Theranova 500® and Elisio 21HX™).
Theranova 500® hemodialysis was very similar in efficacy to OL‐HDF, although with significantly higher albumin loss.
Elisio 21HX™ hemodialysis resulted in a lower removal of molecules with molecular weight around 20 000 compared to OL‐HDF, with no significant differences compared to Theranova 500®, and a lower albumin loss than Theranova 500® and OL‐HDF.</description><subject>Albumin</subject><subject>albumine</subject><subject>Albumins</subject><subject>Albumins - analysis</subject><subject>Dialyzers</subject><subject>Effectiveness</subject><subject>expanded hemodialysis</subject><subject>Hemodiafiltration - methods</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>medium cut‐off dialyser</subject><subject>Metabolomics</subject><subject>Molecular weight</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Nuclear safety</subject><subject>on‐line hemodiafiltration</subject><subject>Prolactin</subject><subject>Prospective Studies</subject><subject>Renal Dialysis - methods</subject><subject>uremic toxins</subject><issn>0160-564X</issn><issn>1525-1594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uVCEUh4mxsWN14QsYEje6uC1c_g3uJhOtTZo0URfubs4At6XhwgiXNuPKR3Dv2_kkpU51YSIhkMDHl3P4IfSCkmPaxgmkfEw5l_IRWlDRi44KzR-jBaGSdELyL4foaSnXhBDFiXyCDpnkPdFsuUA_12naQvYlRZxG3OPJWV8nbOqcxhFbD2H3zeWCb9pSC07x1_cfwUeHr9yU2vXow5xh9u19dpeQrY-X2LptvT-8cRg2Pvh5hyFaDGFTJx9xSKW8xauIazQpzjmF4Cw2TesNhOYpDrK5eoYORgjFPX_Yj9Cn9-8-rz905xenZ-vVeWeYYLJjIAiXICgZLaiNML22TFEplQZjqJZM6d4IkIoQzcfeAidANVVaUaHYEXq9t25z-lpdmYfJF-NCgOhSLUOvmG5TKNHQV_-g16nm2Gpr1FJIKZZMN-rNnjK59ZndOGyznyDvBkqG-7yGltfwO6_Gvnww1k37-b_kn4AacLIHbn1wu_-bhtXFx73yDoCRojA</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Martínez‐Miguel, Patricia</creator><creator>Gimena Muñoz, Rocío</creator><creator>Barrionuevo González, Marta</creator><creator>López‐Ongil, Susana</creator><creator>Moro, María Ángeles</creator><creator>Lizasoain, Ignacio</creator><creator>Rodríguez‐Puyol, Diego</creator><creator>García Segura, Juan Manuel</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4544-7581</orcidid></search><sort><creationdate>202303</creationdate><title>Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research</title><author>Martínez‐Miguel, Patricia ; Gimena Muñoz, Rocío ; Barrionuevo González, Marta ; López‐Ongil, Susana ; Moro, María Ángeles ; Lizasoain, Ignacio ; Rodríguez‐Puyol, Diego ; García Segura, Juan Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-3a5046a510fda7b5c29d3716679acc1963792c5a670094f2da40a1917971573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Albumin</topic><topic>albumine</topic><topic>Albumins</topic><topic>Albumins - analysis</topic><topic>Dialyzers</topic><topic>Effectiveness</topic><topic>expanded hemodialysis</topic><topic>Hemodiafiltration - methods</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>medium cut‐off dialyser</topic><topic>Metabolomics</topic><topic>Molecular weight</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Nuclear safety</topic><topic>on‐line hemodiafiltration</topic><topic>Prolactin</topic><topic>Prospective Studies</topic><topic>Renal Dialysis - methods</topic><topic>uremic toxins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martínez‐Miguel, Patricia</creatorcontrib><creatorcontrib>Gimena Muñoz, Rocío</creatorcontrib><creatorcontrib>Barrionuevo González, Marta</creatorcontrib><creatorcontrib>López‐Ongil, Susana</creatorcontrib><creatorcontrib>Moro, María Ángeles</creatorcontrib><creatorcontrib>Lizasoain, Ignacio</creatorcontrib><creatorcontrib>Rodríguez‐Puyol, Diego</creatorcontrib><creatorcontrib>García Segura, Juan Manuel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Artificial organs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez‐Miguel, Patricia</au><au>Gimena Muñoz, Rocío</au><au>Barrionuevo González, Marta</au><au>López‐Ongil, Susana</au><au>Moro, María Ángeles</au><au>Lizasoain, Ignacio</au><au>Rodríguez‐Puyol, Diego</au><au>García Segura, Juan Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research</atitle><jtitle>Artificial organs</jtitle><addtitle>Artif Organs</addtitle><date>2023-03</date><risdate>2023</risdate><volume>47</volume><issue>3</issue><spage>589</spage><epage>594</epage><pages>589-594</pages><issn>0160-564X</issn><eissn>1525-1594</eissn><abstract>Background
Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on‐line hemodiafiltration (OL‐HDF) and HD with medium cut‐off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL‐HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer.
Methods
Fourteen patients following treatment with OL‐HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1‐week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified.
Results
Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL‐ HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL‐HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p < 0.001, respectively). Metabolomic studies suggested, by semi‐quantitative analysis, a greater depurative capacity of OL‐HDF, followed by Elisio 21HX™, and then Theranova 500®.
Conclusions
In this study, HD with Theranova 500® has proven to be very similar in efficacy to OL‐HDF, although with a significantly higher albumin loss. HD with Elisio 21HX™ resulted in lower removal of molecules around 20 000 compared to OL‐HDF, with no significant difference compared to Theranova 500®, and with less albumin loss than Theranova 500®.
The aim of this study was to compare the efficacy and safety of on‐line hemodiafiltration (OL‐HDF), with hemodialysis with 2 medium cutoff dialyzers (Theranova 500® and Elisio 21HX™).
Theranova 500® hemodialysis was very similar in efficacy to OL‐HDF, although with significantly higher albumin loss.
Elisio 21HX™ hemodialysis resulted in a lower removal of molecules with molecular weight around 20 000 compared to OL‐HDF, with no significant differences compared to Theranova 500®, and a lower albumin loss than Theranova 500® and OL‐HDF.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36420938</pmid><doi>10.1111/aor.14466</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4544-7581</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-564X |
| ispartof | Artificial organs, 2023-03, Vol.47 (3), p.589-594 |
| issn | 0160-564X 1525-1594 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2739739575 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Albumin albumine Albumins Albumins - analysis Dialyzers Effectiveness expanded hemodialysis Hemodiafiltration - methods Hemodialysis Humans medium cut‐off dialyser Metabolomics Molecular weight NMR Nuclear magnetic resonance Nuclear safety on‐line hemodiafiltration Prolactin Prospective Studies Renal Dialysis - methods uremic toxins |
| title | Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T10%3A49%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%202%20medium%20cutoff%20dialyzers%20versus%20on%E2%80%90line%20hemodiafiltration%20regarding%20depurative%20ability%20and%20albumin%20loss:%20An%20uncontrolled%20clinical%20research&rft.jtitle=Artificial%20organs&rft.au=Mart%C3%ADnez%E2%80%90Miguel,%20Patricia&rft.date=2023-03&rft.volume=47&rft.issue=3&rft.spage=589&rft.epage=594&rft.pages=589-594&rft.issn=0160-564X&rft.eissn=1525-1594&rft_id=info:doi/10.1111/aor.14466&rft_dat=%3Cproquest_cross%3E2739739575%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785665839&rft_id=info:pmid/36420938&rfr_iscdi=true |